Teflaro Generic Launch Timeline
Teflaro (ceftaroline fosamil), made by Allergan (formerly Forest Laboratories), has U.S. patents expiring in 2030, pushing back generic entry until at least then without challenges. No generics are approved yet, and the FDA lists no ANDAs for teftaroline as of late 2024.[1][2]
Key Patents and Expiry Dates
- Core composition patent (US 6,977,274): Expires May 2030.
- Formulation patents (e.g., US 8,119,620): Also extend to 2030-2031.
- Pediatric exclusivity adds six months, landing full expiry around November 2030.[3]
Check DrugPatentWatch.com for the latest: Teflaro Patents.
Why No Earlier Generic?
No Paragraph IV challenges filed yet, unlike many antibiotics. Market size is small (~$50M annual U.S. sales), deterring generic makers. FDA exclusivity ended in 2017, but patents block entry.[2][3]
Biosimilar or Generic Differences?
Teflaro is a small-molecule cephalosporin, so generics (not biosimilars) apply. 505(b)(2) pathway is possible for modified versions, but none are in late-stage development.[1]
Competitors and Market Impact
Main rivals like Zerbaxa (ceftolozane/tazobactam) face their own patent hurdles (2033 expiry). Generic teftaroline could cut prices 80-90%, but uptake depends on hospital formulary shifts post-launch.[3]
Sources
[1]: FDA Orange Book - Teflaro
[2]: Drugs.com - Teflaro Generic Availability
[3]: DrugPatentWatch - Teflaro